Loading...

Grant D. Lawless, RPh, MD, FACP

TitleAssociate Professor, Pharmaceutical & Health Economics
InstitutionUniversity of Southern California
DepartmentPharmacology and Pharmaceutical Sciences
Address3335 S. Figueroa Street
Off Campus
Los Angeles CA 90007
Phone+1 213 821 6181
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Oderda GM, Lawless G, Wright GC, Nussbaum SR, Elder R, Kim K, Brixner DI. The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. Per Med. 2018 Apr 25. PMID: 29693487.
      View in: PubMed
    2. Defining Value in Cancer Care: AVBCC 2013 Steering Committee Report. Am Health Drug Benefits. 2013 Jul; 6(5):236-46. PMID: 24991360; PMCID: PMC4031719.
    3. Short LJ, Fisher MD, Wahl PM, Kelly MB, Lawless G, White S, Rodriguez NA, Willey VJ, Brawley OW. Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention. Cancer. 2010 Jan 01; 116(1):193-202. PMID: 19877115.
      View in: PubMed
    4. Lawless G. The working patient with cancer: implications for payers and employers. Am Health Drug Benefits. 2009 Jun; 2(4):168-73. PMID: 25126288; PMCID: PMC4106533.
    5. Joyce GF, Goldman DP, Karaca-Mandic P, Lawless G. Impact of specialty drugs on the use of other medical services. Am J Manag Care. 2008 Dec; 14(12):821-8. PMID: 19067499; PMCID: PMC3767569.
    6. Willey VJ, Kopenski F, Lawless G. Beyond the myths: finding benefit design solutions that address the true costs of high healthcare use. Am J Manag Care. 2008 Jul; 14(8 Suppl):S252-63. PMID: 18672956.
      View in: PubMed
    7. Willey VJ, Pollack MF, Lednar WM, Yang WN, Kennedy C, Lawless G. Costs of severely ill members and specialty medication use in a commercially insured population. Health Aff (Millwood). 2008 May-Jun; 27(3):824-34. PMID: 18474976.
      View in: PubMed
    8. Owens G, Emons MF, Christian-Herman J, Lawless G. Current trends in pharmacy benefit designs: a threat to disease management in chronic complex diseases. Dis Manag. 2007 Apr; 10(2):74-82. PMID: 17444792.
      View in: PubMed
    9. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006 Sep-Oct; 25(5):1319-31. PMID: 16966729.
      View in: PubMed
    10. Morrow T, Siegel M, Boone S, Lawless G, Carter W. Chemotherapy dose intensity determination as a quality of care measure for managed care organizations in the treatment of early-stage breast cancer. Am J Med Qual. 2002 Nov-Dec; 17(6):218-24. PMID: 12487337.
      View in: PubMed
    11. Halbert RJ, Zaher C, Wade S, Malin J, Lawless G, Dubois RW. Outpatient cancer drug costs: changes, drivers, and the future. Cancer. 2002 Feb 15; 94(4):1142-50. PMID: 11920485.
      View in: PubMed
    Grant's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _